Virtual Challenging Case Clinic:
B-Cell Lymphomas

  • Delve into treatment paradigms, available therapies, and agents under development for various subtypes of B-cell lymphomas
  • Expert insights on particularly challenging patient cases submitted by actual attendees
VCC Main image 2
jpleonar 1

Course Director

John P. Leonard, MD
Senior Associate Dean for
Innovation and Initiatives
Executive Vice Chair,
Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology & Medical Oncology
Weill Cornell Medical College
New York, New York

Agenda

  • Welcome, Introductions, and
    Pre-session Survey
  • General Disease State and
    Treatment Guidelines
  • Expert Insights: Faculty-submitted cases
  • Case Presentation, Polling Questions,
    and Discussion
  • Q&A
  • Conclusion and Post-session Survey

Upcoming Webinars

MAY 18, 2022

Mantle Cell Lymphoma
Tycel Phillips, MD
University of Michigan Health | Ann Arbor, Michigan

JUNE 8, 2022

CAR T-cell Therapy
Mehdi Hamadani, MD Medical College of Wisconsin | Milwaukee, Wisconsin

JULY 13, 2022

Updates from ASCO and EHA
Gilles Salles, MD, PhD
Memorial Sloan Kettering Cancer Center | New York ,New York

AUGUST 10, 2022

Hodgkin’s Lymphoma
Ann LaCasce, MD
Dana-Farber Cancer Institute | Boston, Massachusetts

SEPTEMBER 14, 2022

CNS Lymphoma
Alvaro Alencar, MD
University of Miami Sylvester Comprehensive Cancer Center | Miami, Florida

NOVEMBER 9, 2022

Chronic Lymphocytic Leukemia
Jennifer Brown, MD, PhD
Dana-Farber Cancer Institute | Boston, Massachusetts

DECEMBER 14, 2022

Diffuse Large B-cell Lymphoma
Julie Vose, MD, MBA
University of Nebraska Medical Center | Omaha, Nebraska

FEBRUARY 8, 2023

Marginal Zone Lymphoma
Peter Martin, MD
Weill Cornell Medicine | New York, New York
This activity is jointly provided by the University of Nebraska Medical Center and Bio Ascend. This activity is supported by independent educational grants from Abbvie Inc., AstraZeneca, Genmab, Lilly, and Merck & Co. Inc.
Recordings From Previous Webinars: 2022 Series
Mantle Cell Lymphoma
Tycel Phillips, MD
University of Michigan Health l Ann Arbor, Michigan
Broadcast May 18, 2022

Recordings From Previous Webinars: 2021 Series

Recordings From Previous Webinars: 2021 Series

Follicular Lymphoma​
Carla Casulo, MD
University of Rochester Medical Center | Rochester, New York
Broadcast February 9, 2022
Series Review​
John Leonard, MD
Weill Cornell Medicine | New York, New York
Broadcast March 9, 2022

Virtual Challenging Case Clinic: B-cell Lymphomas: Updates from ASH 2021

John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Broadcast January 12, 2022

Virtual Challenging Case Clinic: B-cell Lymphomas: MZL

Leo I. Gordon, MD
Northwestern University | Chicago, IL
John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Broadcast December 8, 2021
Virtual Challenging Case Clinic: B-cell Lymphomas: DLBCL
Grzegorz Nowakowski, MD
Mayo Clinic | Rochester, MN
John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Broadcast November 10, 2021

Virtual Challenging Case Clinic: B-cell Lymphomas: CLL

Matthew Davids, MD, MMSc
Dana-Farber Cancer Institute | Boston, MA
John P. Leonard, MD
Weill Cornell Medicine | New York, New York

Broadcast October 13, 2021

Virtual Challenging Case Clinic: B-cell Lymphomas: Primary CNS Lymphoma

James Rubenstein, MD
University of California San Francisco | San Francisco, CA
John P. Leonard, MD
Weill Cornell Medicine | New York, New York

Broadcast September 15, 2021

Virtual Challenging Case Clinic: B-cell Lymphomas:
Updates from ASCO, EHA, and ICML

John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Gilles Salles, MD, PhD
Memorial Sloan Kettering | New York

Broadcast August 11, 2021

US National Clinical Trial Update Roundtable

John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Brad Kahl, MD
Washington University School of Medicine | Saint Louis, Missouri
Jonathan Friedberg MD, MMSc
University of Rochester Medical Center | Rochester, New York

Broadcast July 14,2021

Hodgkin’s Lymphoma

Ann LaCasce, MD
Dana-Farber Cancer Institute | Boston, Massachusetts

Broadcast June 9, 2021

CAR T-cell Therapy

Mehdi Hamadani, MD
Medical College of Wisconsin | Milwaukee, Wisconsin

Broadcast May 12, 2021

Mantle Cell Lymphoma

Jonathon Cohen, MD, MS
Winship Cancer Center of Emory University | Atlanta, Georgia

Broadcast on April 14, 2021

Recordings From Previous Webinars: 2020 Series

Updates from ASH and Year in Review

John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Broadcast on January 13, 2021

Follicular Lymphoma

Jonathon Cohen, MD, MS
Winship Cancer Institute of Emory University | Atlanta, Georgia
Broadcast on December 9, 2020

Marginal Zone Lymphoma

Peter Martin, MD
Weill Cornell Medicine | New York, New York
Broadcast on November 11, 2020

T-cell Lymphoma

Kerry Savage, MD
University of British Columbia | Vancouver, Canada
Broadcast on October 14, 2020

Hodgkin Lymphoma

Jonathan Friedberg, MD, MMSc
University of Rochester Medical Center | Rochester, New Yorkj
Broadcast on September 9, 2020

Updates from ASCO and EHA

John P. Leonard, MD
Weill Cornell Medical College | New York, New York
Broadcast on August 12, 2020

Chronic Lymphocytic Leukemia

Matthew Davids, MD, MMSc
Dana-Farber Cancer Institute | Boston, Massachusetts
Broadcast on July 8, 2020

Transformed Lymphoma

Andrew Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center | New York, New York
Broadcast on June 10, 2020

Diffuse Large B-cell Lymphoma

Mitchell Smith, MD, PhD
George Washington University | Washington, District of Columbia
Broadcast on May 13, 2020

CAR T-Cell Therapy

Julie Vose, MD, MBA
University of Nebraska Medical Center | Omaha, Nebraska
Broadcast on April 8, 2020

This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.

Target Audience

The target audience for this activity is clinicians who treat patients with indolent and aggressive B-cell lymphomas: hematologists, medical oncologists, oncology nurses, nurse practitioners, oncology pharmacists, and other healthcare professionals.

Learning Objectives

After completing this activity, participants should be better able to:

  • Assess best available evidence regarding treatment of indolent and aggressive B-cell lymphomas
  • Evaluate the clinical implications of emerging data regarding B-cell lymphoma treatment approaches
  • Plan strategies to address complicated B-cell lymphoma cases
Continuing Education

UNMC Joint Accreditation Logo December2020 1

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The University of Nebraska Medical Center, Center for Continuing Education designates this live activity for a maximum of 1 AMA PRA Category 1 Creditâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  
Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC or Bio Ascend.

This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, and Epizyme, Inc.